PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

REHOVOT, Israel and JERSEY CITY, New Jersey, October 2 /PRNewswire/ --

- The Study Will Compare the Results of Rosetta Genomics' microRNA-based Test, miRview(TM) Squamous, Which Differentiates Squamous From non Squamous non Small Cell Lung Cancer, With Current Diagnostic Methods

- A Test Based on the miRview(TM) Technology First Approved for Clinical use Through Columbia University's High Complexity Molecular Pathology Lab Earlier This Year

- Rosetta Genomics is Expecting to Launch miRview(TM) Squamous Later This Year Through its Recently Acquired CLIA lab in Philadelphia

REHOVOT, Israel and JERSEY CITY, New Jersey, October 2 /PRNewswire/ --

SAN JOSE, California, October 2 /PRNewswire/ --

Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in application-optimized, high performance server solutions, today announced that its SuperServer 6015W-NTR earned the top honor from GCN (Government Computer News) over competitive product offerings from HP, Dell and Fujitsu based on GCN Lab test results. Supermicro's SuperServer 6015W-NTR was the only server to earn straight A's and proved superior to the others on both performance and value.

GENEVA, October 2 /PRNewswire/ --

- Actress, Producer and Mother Salma Hayek Calls for Participation in Campaign to Eliminate Disease Responsible for the Death of one Newborn Baby Approximately Every Three Minutes

A global review confirms that the elimination of maternal and newborn tetanus, preventable diseases responsible for the death of one baby approximately every three minutes and up to 30,000 mothers each year, could be achieved by 2012, and encourages the public to participate in a high profile campaign to help those most at risk.

PARIS, October 2 /PRNewswire/ -- As a sponsor of Mitsubishi Motors Motor Sports, Valeo will equip the new Mitsubishi Racing Lancer for the 2009 Dakar Rally with a new engine cooling system offering 5% fuel savings. The Lancer is also equipped with Valeo's LED daytime running lights.

Unique engine cooling management

PARIS, October 2 /PRNewswire/ -- Valeo's driving assistance systems act as virtual co-pilots, assisting the driver's own eyes. Based on its full range of radar, ultrasonic and camera surveillance systems, Valeo offers solutions that monitor the vehicle's environment and provide the driver with 360degrees vision thus enhancing safety and driving comfort during low-speed maneuvers.